CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD.
Yuan J, et al. Among authors: wolchok jd.
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5. doi: 10.1073/pnas.0810114105. Epub 2008 Dec 12.
Proc Natl Acad Sci U S A. 2008.
PMID: 19074257
Free PMC article.
Clinical Trial.